sanofi India Limited has scheduled an investor and analyst conference call for August 5, 2026, to provide an update on its unaudited financial results for the quarter and half-year ended June 30, 2026. The meeting, set for 4:00 p.m. to 5:00 p.m. IST, offers stakeholders a direct channel to engage with management regarding the company’s recent financial performance and strategic outlook. This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Logistics

The company has facilitated access through multiple channels, including universal dial-in numbers and a one-way audio webcast. International participants can join via toll-free numbers designated for specific regions. To participate in the question-and-answer session, investors must pre-register by 12:00 p.m. IST on August 5, 2026. Questions will be addressed in the sequence of registration.

Participation Guidelines

Pre-registration is mandatory for those wishing to ask questions during the session. The registration window closes at 12:00 p.m. IST on the day of the event. Participants who register will have the opportunity to view the presentation and pose questions to the management team. For those unable to join via phone, a one-way audio webcast will be hosted simultaneously.

International investors can access the call using toll-free numbers available for countries including the USA, UK, Australia, Japan, Germany, France, China, and others. The company has ensured broad accessibility to accommodate global stakeholder interest in its FY26 performance metrics.

Sanofi India Limited disclosed the resignation of Mr. Rachid Ayari as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel, effective from the close of business hours on September 30, 2026. The resignation follows his decision to transition to another role within the Sanofi group. Consequently, Mr. Ayari will also cease to be a member of the Risk Management Committee and Senior Management Personnel on the same date.

The company acknowledged Mr. Ayari's contributions, noting his valuable guidance and dedicated assistance during his tenure. Sanofi India is currently in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be designated as Key Managerial Personnel. The stock exchanges will be informed of the appointment in due course.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirmed that there are no other material reasons for the resignation apart from the transition within the group.

Key Details of Resignation